Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Locally advanced rectal cancer (LARC) carries a substantial risk of recurrence, prompting the use of neoadjuvant chemoradiotherapy (nCRT) to improve tumor resectability and long-term outcomes. However, individual treatment responses vary considerably, highlighting the need for robust predictive tools to guide clinical decision-making.

Aim: To develop a nomogram model integrating clinical characteristics and biomarkers to predict the likelihood of poor response to nCRT in LARC.

Methods: A retrospective analysis was performed on 178 patients with stage II-III LARC treated from January 2021 to December 2023. All patients underwent standardized nCRT followed by total mesorectal excision. Clinical data, inflammatory markers [C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha], and tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen 19-9] were collected. Logistic regression was used to identify independent predictors of poor nCRT response. A nomogram was constructed using significant predictors and validated concordance index (C-index), receiver operating characteristic curve, calibration plot, and decision curve analysis (DCA).

Results: A total of 178 patients were enrolled, with 36 (20.2%) achieving a good response and 142 (79.8%) exhibiting a poor response to nCRT. Baseline factors, including age and comorbidities, showed no significant differences. However, poor responders more frequently had lymph node metastasis, advanced tumor node metastasis/T stage, larger tumor diameter, and elevated CRP, IL-6, and CEA levels. Logistic regression confirmed CRP, IL-6, and CEA as independent predictors of poor response. The nomogram demonstrated high accuracy (area under the curve = 0.928), good calibration (Hosmer-Lemeshow = 0.928), and a sensitivity of 88.1% with 82.6% specificity. Internal validation bootstrap resampling ( = 1000) yielded an adjusted C-index of 0.716, and DCA confirmed substantial clinical utility.

Conclusion: A nomogram incorporating serum CRP, IL-6, and CEA accurately predicts poor nCRT response in patients with LARC. This model provides a valuable framework for individualized treatment planning, potentially improving clinical outcomes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278235PMC
http://dx.doi.org/10.4251/wjgo.v17.i7.105403DOI Listing

Publication Analysis

Top Keywords

poor response
12
crp il-6
12
il-6 cea
12
nomogram model
8
neoadjuvant chemoradiotherapy
8
locally advanced
8
advanced rectal
8
rectal cancer
8
response ncrt
8
178 patients
8

Similar Publications

Activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL) is an aggressive cancer with poor response to standard chemotherapy. In search of new therapeutic leads, a library of 435 fractions prepared from the Irish marine biorepository was screened against 2 ABC-DLBCL cell lines (TMD8 and OCI-Ly10) and a non-cancerous control cell line (CB33). Active fractions are prioritized based on potency and selectivity.

View Article and Find Full Text PDF

Mitochondrial ClpX Inhibition Induces Ferroptosis and Blocks Pancreatic Cancer Cell Proliferation.

Chembiochem

September 2025

School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, P. R. China.

The ATPase caseinolytic protease X (ClpX), forming the ClpXP complex with caseinolytic protease P (ClpP), is essential for mitochondrial protein homeostasis. While ClpP targeting is a recognized anticancer strategy, the role of ClpX in cancer remains underexplored. In pancreatic ductal adenocarcinoma (PDAC), elevated CLPX expression correlates with poor prognosis, suggesting its oncogenic function.

View Article and Find Full Text PDF

Is every pancreatic cancer patient a palliative care patient?

Ann Palliat Med

September 2025

Brown University Health Cancer Institute, Providence, RI, USA; Division of Geriatrics and Palliative Medicine, Department of Medicine, Alpert Medical School of Brown University, Providence, RI, US.

ancreatic cancer is an aggressive disease and often presents at an advanced stage with no curative options. The disease is often characterized by rapid progression, limited or short-lived responsiveness to standard therapies, and a profound impact on patients' quality of life. Despite advances in targeted therapies and immunotherapy, curative outcomes remain elusive for the majority of patients with advanced or high-grade disease with a 5-year survival rate of less than 10%.

View Article and Find Full Text PDF

Elesclomol-Copper combination synergistically targets mitochondrial metabolism in cancer stem cells to overcome chemoresistance in pancreatic ductal adenocarcinoma.

Mol Ther

September 2025

Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China; State Key Laboratory of Systems Medicine for Cancer, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Pancreatic Cancer Heterogeneity, Candiolo Cancer Institute

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor prognosis, partly due to cancer stem cells (CSCs) that drive progression and treatment resistance. We explored the therapeutic potential of inducing cuproptosis, a copper-dependent regulated cell death, in CSC-enriched PDAC models. Using human and murine PDAC models, we evaluated elesclomol, a copper transport enhancer.

View Article and Find Full Text PDF

Objectives: Salvage endoscopic therapy is increasingly recommended for localized, superficial failure at the primary site after chemoradiotherapy for esophageal squamous cell carcinoma. This multicenter retrospective study aimed to evaluate the clinical outcomes and prognostic factors associated with overall survival in patients who underwent salvage endoscopic therapy for cT1N0M0 local failure after chemoradiotherapy or radiotherapy for esophageal squamous cell carcinoma.

Methods: We retrospectively analyzed patients with cT1N0M0 local failure after chemoradiotherapy or radiotherapy who underwent endoscopic resection or photodynamic therapy using talaporfin sodium at two Japanese institutions between 2012 and 2021.

View Article and Find Full Text PDF